A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial

Conclusions
In patients with ISR, treatment with DEB was noninferior compared with DES in terms of 6-month MLD. There were no differences in clinical endpoints, including target vessel revascularization up to 12 months. Therefore, use of a DEB is an attractive treatment option for in-stent restenosis, withholding the need for additional stent implantation.

Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 5, 2018 Category: Cardiology Authors: Baan, J., Claessen, B. E., Dijk, K. B.-v., Vendrik, J., van der Schaaf, R. J., Meuwissen, M., van Royen, N., Gosselink, A. T. M., van Wely, M. H., Dirkali, A., Arkenbout, E. K., de Winter, R. J., Koch, K. T., Sjauw, K. D., Beijk, M. A., Vis, M. M., Wykrzy Tags: Coronary Source Type: research